Pharma & Life Sciences

Anticipate risks, uncover opportunities and drive innovation in pharma.

The only AI-powered strategic intelligence platform that transforms global market shifts into high-impact decisions for pharma leaders navigating industry disruption.

Talk to an expert
Our solution

Discover, analyse and forecast trends on autopilot

Trendtracker cuts through global big data overload, connecting thousands of trusted pharma sources into one platform. Instantly surface the trends that matter, anticipate industry shifts early, and make strategic decisions in real time your company stays ahead of disruption.

trend board visualtrend board visualtrend board visualtrend board visual
Two planets in space with one glowing purple and having delicate glowing purple rings against a dark starry background.

Spot opportunities sooner than anyone else

Our AI surfaces signals from billions of global data points, giving your team a strategic edge on emerging disruptions—with prioritized recommendations tailored to your industry.

AI Analyst for pharma leaders

Receive exclusive strategic advice powered by Trendtracker’s proprietary global database—far deeper than public LLMs or Internet sources.

See your global energy landscape clearly

Automatically visualize trend radars for continuous, real-time insights on emerging energy shifts.

Track trends in real time

Stay ahead, not just updated. Track how market trends evolve, analyze with AI, and gain deeper strategic intelligence to inform decisions.
Abstract background with smooth gradients blending dark and light purple hues.
Three things that make the difference

Signal intelligence built for pipeline decisions that take years to reverse

Not every emerging science signal warrants investment

Trendtracker scores and ranks signals continuously across scientific research, clinical development, regulatory frameworks, and investment flows - so your R&D and strategy teams distinguish platforms approaching viability from those still speculative.

A pipeline bet without a source chain is just a hypothesis

From live signal to BD recommendation, every source stays visible and traceable at every step - so the intelligence behind every licensing or investment decision holds up to scrutiny.

Siloed scanning produces contradictory R&D and regulatory decisions

Shared access controls ensure R&D, regulatory affairs, and strategy scan the same intelligence base - keeping every function aligned on what is actually moving across science, regulation, and competition.
Trends in the industry

Top three emerging trends shaping the industry

AI-Driven Drug Discovery
78
%
6.4

Insights

What's happening globally?

AI-driven drug discovery is experiencing accelerated growth with significant investments and collaborations among industry leaders. These partnerships aim to reduce drug development timelines and costs, indicating a rising trend likely to sustain long-term impact.

What does this mean for the industry?

AI in drug discovery boosts speed and cost efficiency, reshaping R&D investments and timelines. Companies notice immediate impacts in the drug pipeline and operational costs, resulting in efficiencies. AI developments change competitive dynamics, prompting regulatory adaptations and focus on digital innovation. Companies increasingly face pressure to integrate robust AI systems, affecting investment strategies towards AI infrastructure.

What are the key strategic actions?

Form strategic partnerships with AI companies to boost R&D in drug development, focus on reducing time and cost, and enhance AI integration for precision medicine. Collaborations with tech giants can accelerate innovation, meet regulatory demands, and improve market access, leading to more effective patient-centric treatments.

RNA Therapeutics
72
%
3.8

Insights

What's happening globally?

The pharmaceutical industry's focus on digital transformation, such as using AI and RFID technology, is crucial for enhancing supply chain resilience. This improves risk management and operational efficiency, strengthening the industry's ability to adapt to disruptions.

What does this mean for the industry?

Diversification of supply sources and collaborations with local facilities can immediately stabilize raw material availability and reduce the risk of interruptions, directly impacting manufacturing efficiency and cost management. Strengthened supplier relationships and enhanced supply chain resilience contribute to long-term competitive advantages, affecting market dynamics, customer satisfaction, and regulatory confidence in pharmaceutical products

What are the key strategic actions?

Pharmaceutical companies could advance supply chain resilience by investing in domestic manufacturing, reducing dependency on foreign suppliers, and enhancing FDA compliance. This could ensure drug quality and availability, aligning with regulatory demands and supporting operational efficiency. Governments and investors may favorably view this proactive resilience building.

Precision Medicine
18
%
9.5

Insights

What's happening globally?

Precision medicine is transforming drug development, enabling more accurate treatment options through integrating biomarkers and genetic data. This shift can lead to improved patient stratification, offering tailored therapies that enhance treatment efficacy and safety, ultimately reshaping pharmaceutical strategies.

What does this mean for the industry?

The shift to precision medicine leads to targeted therapies, improving drug efficacy and reducing adverse effects. This can optimize the drug approval process, shortening time to market and enhancing revenues from innovative products. Precision medicine's personalized treatments increase R&D costs but promise better patient outcomes, leading to enhanced trust from healthcare providers and patients. This also attracts more investment due to potential breakthroughs in chronic disease management.

What are the key strategic actions?

Leverage biomarkers to accelerate precision medicine in R&D. By integrating robust biomarker strategies in drug development, the company can enhance patient stratification and tailor effective therapies, optimizing both patient outcomes and regulatory compliance. This aids R&D excellence and supports efficient market expansion

Need clarity?
You’re in the right place.

Can Trendtracker detect signals across patents, scientific publications, VC funding and M&A activities?

Trendtracker continuously monitors patents, peer-reviewed research, venture funding, and M&A activity across {{sources}}+ curated sources. Insights are traceable to the underlying sources, so findings can be verified and shared with confidence. This gives R&D and strategy teams early visibility into where scientific momentum is building and where investment is concentrating, before those signals reach mainstream analyst coverage.

How accurately does Trendtracker handle specialised terminology - where one compound carries a generic name, a brand name and a research code?

Trendtracker is designed to recognize the specific terminology used in life sciences as they appear across scientific literature, patents, regulatory filings, and investment data - so trend scores reflect the complete picture of activity, not a partial one.

What does Trendtracker add for a pharma foresight team that already uses trend and market-intelligence tools?

Most existing tools deliver depth at a point in time. Trendtracker adds what sits between those reports - a continuously updated intelligence layer that scores each trend by Strength and Momentum on a normalised scale, so signals are always directly comparable without manual effort. Teams spend less time maintaining the process and more time acting on what it surfaces.

How does Trendtracker support competitive intelligence in pharma, like competitors in adjacent therapeutic areas?

Trendtracker surfaces competitor activity alongside the scientific and regulatory shifts behind it - so teams see not just what a competitor is developing, but which broader move they may be responding to. It also brings less obvious competitors into view from adjacent areas, helping teams judge whether a pipeline move points to a wider therapeutic shift or an isolated bet before committing to a position.

Can Trendtracker insights be shared across pharma R&D, innovation, strategy and foresight teams?

Yes. Different teams across the organisation work from the same continuously updated intelligence, each focused on the trends and domains relevant to their function. This makes trend intelligence a shared reference point rather than a set of parallel analyses running in isolation - reducing duplication and keeping every function aligned on the same evolving picture.

Related insights

Read more
Customer Story
All

P&G's Ingredient Innovation Accelerates Breakthrough Products from Idea to Launch

Strategic Intelligence
8 min read
All

Foresight-driven Innovation: How to build a future-proof innovation portfolio

Strategic Intelligence
6 min read
All

Early Warning Systems: How Organizations Detect Strategic Risks Before Disruption Occurs

Strategize smarter with Trendtracker

Drowning in data? See how Trendtracker’s AI turns information overload into instant, actionable clarity for pharma strategists.

Talk to an expert